Site Map

Pages

• About us
• Contact
• CV-Nathalie-Accornero
• Events
  • Blue Biotech Events
  • Green Biotech Events
  • In Vitro Diagnostic Events
  • Medtech Events
  • Neutraceutic & Comestic events
  • Pharma & Biotech Events
• Former Events 2013
  • Blue Biotech Events 2013
  • Green Biotech Events 2013
  • In Vitro Diagnostic Events 2013
  • Neutraceutic & Cosmetic Events 2013
  • Pharma & Biotech Events 2013
• Former Events 2014
  • Blue Biotech Events 2014
  • Green Biotech Events 2014
  • In Vitro Diagnostic Events 2014
  • Neutraceutic & Comestic events 2014
  • Neutraceutic & Comestic events 2014
  • Pharma & Biotech event 2014
• Former Events 2015
  • Green Biotech Events 2015
    • Blue Biotech Events 2015
  • In Vitro Diagnostic Events 2015
  • Neutraceutic & Comestic events 2015
  • Pharma & Biotech Events 2015
• Former Events 2016
  • In Vitro Diagnostic Events 2016
• Mission of Prospection by phone & e-mail
• News
• Outsource your preparation for your next business convention
• Pharma & Biotech event 2016
• Register to Btobio Innovation News
• Services in BD
  • Operational Level
    • E- mailing-Campaign
    • Monitor your traffic on your website
    • Presenting Video
  • Strategic Level
• Why Outsourcing ?

Posts

• Download
  • Abivax reports positive phase 2b results of ABX464 in ulcerative colitis
  • Download-BioEurope-Spring2015
  • Download Biofit-2014
• News
  • Meet us at BIOFIT2022, Strasbourg November 29 & 30 or December 7 & 8
  • Meet us on Biotechgate Digital Partnering from November 28- December 2, 2022
  • Meeting us at Biotechgate Digital Partnering Feb7-11, 2022
  • MEETING US AT BIOTECHGATE DIGITAL PARTNERING NOV29-DEC3, 2021
  • Helping you to prepare next BIO-EUROPE Oct 25-28, 2021
  • Meeting us at Biotechgate Digital Partnering & Infectious Diseases Virtual Partnering
  • BIOFIT2019 – very successful Business convention and Congress #BIOFIT2019
  • 2 new services to help the Marketing Manager & the Business Developer
  • Btobioinnovation wishes you a happy New Year 2018
  • Biopharmaceutical News Week 12- 2016
  • Biopharmaceutical News Week 11- 2016
  • Biopharmaceutical News Week 10- 2016
  • Biopharmaceutical News Week 9- 2016
  • Biopharmaceutical News
  • Biopharmaceutical News Week 8- 2016
  • Biopharmaceutical News Week 7- 2016
  • Singapore Biopolis
  • Biopharmaceutical News Week 6- 2016
  • Biopharmaceutical News Week 5- 2016
  • Biopharmaceutical News Week 4- 2016
  • Biopharmaceutical News Week 3- 2016
  • Biopharmaceutical News Week 2- 2016
  • Pharma-Biotech and IVD events
  • Biopharmaceutical News Week 1- 2016
  • Biopharmaceutical News Week 52
  • Biopharmaceutical News Week 51
  • Biopharmaceutical News Week 50
  • Biopharmaceutical News Week 49
  • Biofit 2015, Immunology & oncology
  • Biopharmaceutical News Week 48
  • A way forward for pricing new pharmaceuticals
  • Biopharmaceutical News Week 47
  • Biopharmaceutical News Week 46
  • Biopharmaceutical News Week 45
  • Biopharmaceutical News Week 44
  • Biopharmaceutical News Week 43
  • Biopharmaceutical News Week 42
  • Biopharmaceutical News Week 41
  • Innovation Days
  • Biopharmaceutical News Week 40
  • Biotech-Pharma News
  • Biopharmaceutical News Week 39
  • Biopharmaceutical News Week 38
  • Biopharmaceutical Newsletter Feedback
  • Biopharmaceutical News Week 37
  • Biopharmaceutical News Week 36
  • Biopharmaceutical News Week 35
  • Biopharmaceutical News Week 34
  • Biopharmaceutical News Week 33
  • Biopharmaceutical News Week 32
  • Biopharmaceutical News Week 31
  • Biopharmaceutical News Week 29/30
  • Biopharmaceutical News Week 28
  • Biopharmaceutical News Week 27
  • Biopharmaceutical News Week 26
  • Biopharmaceutical News Week 25
  • Biopharmaceutical News Week 24
  • The Breakthrough of immunotherapy
  • Biopharmaceutical News Week 23
  • Biopharmaceutical News Week 22
  • Biopharmaceutical News Week 21
  • Biopharmaceutical News Week 19-20
  • Biopharmaceutical News Week 18
  • Biopharmaceutical News Week17
  • Biopharmaceutical News Week16
  • Biopharmaceutical News week 15
  • Biopharmaceutical News Week 14
  • Biopharmaceutical News Week 13
  • Biopharmaceutical News Week 12
  • Biopharmaceutical News Week 11
  • Bio-Europe Spring 2015
  • Biopharmaceutical News Week 10
  • Meeting us at Bio-Europe Spring 2015
  • Biopharmaceutical News Week 9
  • Biopharmaceutical News Week 8
  • 2015 A turning point for the biopharma industry?
  • Biopharmaceutical News Week7 2015
  • Biopharmaceutical News week 6 2015
  • Biopharmaceutical News week 5 2015
  • Biopharmaceutical News week 4 2015
  • Biopharmaceutical News Week 2 2014
  • Biopharmaceutical News Highlights 2014
  • Biopharmaceutical News Week 51 2014/
  • Biopharmaceutical News Week 50 2014
  • Biopharmaceutical News Week 49 2014
  • Biopharmaceutical News Week 48 2014
  • Biopharmaceutical News Week 47 2014
  • Biopharmaceutical News week46 2014
  • Biopharmaceuticals News week 43 2014
  • Biopharmaceutical News week42 2014
  • Be represented at CPhI, ICSE, JIB, Bio-Europe & Biofit to find New customers or Partners
  • Biopharmaceutical-News-Week41-2014
  • Biopharmaceutical-News-Week40-2014
  • Biopharmaceutical-News-week39-2014
  • Biopharmaceutical News-Week38
  • Biopharmaceutical Newsweek 36 2014
  • Biopharmaceutical Newsweek 35 2014
  • PERSONALIZED MEDICINE NOW
  • New markets in China: High opportunities for French SME
  • 1st Annual Translational Medicine Partnership Summit, China
  • The New Chinese Markets
  • Biopharmaceutical News-Week22-2014
  • China News
  • Biopharmaceutical News-Week21-2014
  • Reshaping the European pharmaceutical industry
  • Biopharmaceutical News-Week20-2014
  • Biopharmaceutical-News-Week19-2014
  • Biopharmaceutical News-Q1results-New strategies
  • Monitor new prospects engagement
  • Marketing & Business Development News & Tips
  • Compare the attractivity of your website to similar business in Bio
  • Stay in the mind of your prospects
  • ChinaBio Partnering Forum 2014
  • Bio-Europe Spring 2014
  • China business trip to prepare french chinese B to B events in 2014
  • The SME Forum France – China
  • The China Healthcare Investment Conference
  • China’s top priorities for 2014
  • Develop Biobusiness in China
  • Where meeting us in 2014
  • All News
  • Nutraceuticals News
  • Cosmetics News
  • Molecular diagnostics News
  • In Vitro Diagnostic at MEDICA
  • China Forum 2013
  • Demistifying the Chinese Economy
  • Investigating the Alzheimer’s disease puzzle
  • Qiagen, Suzhou, China –May 2013
  • 8th International China Pharmaceutical R&D Summit
  • Vitafoods Europe – May 2013
  • BIO International Convention 2013
  • In cosmetics – Avril 2013
  • Small molecules or biologics?
  • Bio-Europe Spring 2013 – March 2013
  • Where meeting us in 2013
  • Biofit – December 2012
  • J I B – November 2012
  • Buzz4Bio – October 2012
  • Bio Europe – Spring 2012
• Prospection
  • Need help to prepare next Bio-Europe Business Convention, March 28-30, 2022 & April, 4-6 ?
  • Being helped to prepare Next Bio Digital June 8-12, 2020 #BIO2020
  • Be helped to prepare or represented at next Bio-Europe Spring in Paris, March23-25, 2020
  • Meeting us at BIOFIT2019 -Marseille-France- 10-11-December 2019
• Unfiled
  • Pétrole et semi-conducteurs :  Une histoire qui se répète mais qui ne se ressemble pas.
  • Oil and semiconductors: a story that repeats itself but is not the same.
  • Stroke : An update
  • Hearing loss and aging
  • The Top 10 Biopharmaceutical M&A deals of 2023.
  • 2024 Perspectives for Biotechnology Companies
  • US FDA/CDER Novel Drug Approvals for 2023
  • US FDA approves Valneva’s IXCHIQ, the world first chikungunya vaccine.
  • The analysis of biopharma R&D needs to be improved.
  • An Approval and an Inventive Step in Alzheimer’s Disease.
  • Top 20 Biopharmaceutical Companies by 2022 Revenue.
  • Top 10 Biopharmaceutical R&D Budgets in 2022
  • Down Syndrome and Alzheimer’s Disease.
  • The Alzheimer’s puzzle isn’t yet solved.
  • Alzheimer’s Disease Conundrum
  • US FDA approves Lecanemab for the treatment of Alzheimer’s disease.
  • US Congressional report faults FDA and Biogen for Alzheimer’s drug approval
  • Additional Comments on the CTAD annual conference
  • TauRx reports confusing results with HMTM in Alzheimer’s disease treatment
  • A commentary on lecanemab’s recent results published in Science
  • Eli Lilly announced that Donanemab reduces brain amyloid clearance in a Phase 3 study.
  • Eisai’s lecanemab shows positive cognitive effects in Alzheimer’s disease.
  • Lecanemab in Alzheimer’s Disease
  • A Link between Reactivation of the Herpes Virus HSV-1 and Alzheimer’s disease?
  • More bad news for patients with Alzheimer’s disease.
  • European Biotechnology Companies Valuation in decline.
  • Biogen is looking for a new CEO.
  • The Top 20 Pharma Companies by 2021 Revenue
  • Alzheimer’s Disease
  • Stroke
  • Oncology Drug Approvals in 2021
  • Digest of the 2022 JPMorgan Healthcare Conference
  • U.S. FDA approves 63 new treatments in 2021
  • US FDA approves Paxlovid   
  • Age Related Macular Degeneration.
  • Human Induced Pluripotent Stem Cells as Innovative Therapies
  • Molnupiravir efficacy: an update
  • The U.K. approves Molnupiravir for the treatment of COVID-19
  • Alzheimer’s disease treatments (Part 3)
  • European Biotechnology Companies
  • SPECIAL REPORT #21.21
  • SPECIAL REPORT #21.20
  • Alzheimer’s disease treatments (follow up)
  • Alzheimer’s disease treatments
  • The FDA grants an accelerated approval for Biogen’s aducanumab for the treatment of Alzheimer’s disease
  • Top Pharma’s R&D Profile in Q1 2021
  • The Top 20 Drugs and Vaccines by Worldwide Sales in 2020
  • Focus on some European Biotechnology Companies
  • COVID-19 Vaccines. Update #7
  • Top 10 BioPharma R&D Budgets
  • COVID 19 Update #6
  • COVID 19 Update #5
  • Oncology 2020 Update
  • COVID 19. Update #4
  • COVID 19. Update #3
  • COVID 19 Treatments Update #2
  • Novel Drug Approvals for 2020
  • COVID-19 Vaccines: Update #1 (21)
  • Novo and AB Science with positive Alzheimer’s results
  • US FDA grants EUA to Pfizer/BioNTech COVID-19 vaccine
  • COVID-19 News (week 50)
  • U.K. grants Pfizer/BioNTech Emergency Use for their COVID-19 Vaccine.
  • AstraZeneca-Oxford Vaccine News
  • Progress in COVID-19 Treatments
  • Pfizer/BioNtech file EUA for their COVID-19 vaccine
  • Sécurité et tolérance d’un vaccin COVID-19
  • BioNTech et Pfizer enregistrent un premier succès dans lutte contre la COVID-19
  • Covid Vaccine in Germany
  • SPECIAL REPORT COVID-19
  • COVID Treatments (part 3)
  • COVID Treatments (continued)
  • COVID Vaccine Development (continued)
  • Being helped to prepare Next BIO-EUROPE DIGITAL, OCT26-29, 2020
  • COVID Vaccine Development
  • Siemens acquires Varian for $16.4 billion
  • COVID-19: What Asia and Pacific Are Telling Us
  • COVID-19: What have we learned.
  • Takeda licenses seven CNS programs to Neurocrine.
  • Mpro: A potential antiviral target for a SARS-CoV-2
  • Merck makes major moves to enter the COVID-19 arena
  • AstraZeneca’s AZD1222 COVID-19 vaccine enters phase 2/3 clinical trial
  • Moderna Announces Positive Interim Phase 1 Results with mRNA-1273
  • News on Coronavirus Treatments
  • Remdesivir meets primary endpoint in pivotal COVID-19 study
  • Coronavirus Treatment Tracking
  • Remdesivir trials on hold in China
  • COVID-19: The Lockdown
  • COVID-19: A few early lessons.
  • Un peu de Virologie
  • Slowing down coronavirus by “Flattening the Curve”
  • Biopharmaceutical Profitability and Costs of R&D Success
  • Artificial Intelligence used to discover a potent antibiotic
  • COVID-19: Ongoing Activities (Part 2)
  • 2019-nCoronavirus: Ongoing Activities
  • Hearing loss: A major unmet medical need.
  • US FDA Approves 48 New Drugs in 2019
  • 2019 Major Pivotal Clinical Trials Failures
  • Sanofi Capital Markets Day
  • Novartis R&D Day
  • The Top 10 Biopharmaceutical recent M&A Failures
  • US Drug Pricing (Part 2)
  • Happy Thanksgiving
  • Europe approves Merck’s Ebola Vaccine